Cargando…
Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
Introduction: To realize the global goals of eliminating hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030, it is necessary to monitor the status of disease among target populations and undertake the required interventions. This study is the third round of surveys to determine the prevalen...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619467/ https://www.ncbi.nlm.nih.gov/pubmed/34832678 http://dx.doi.org/10.3390/pathogens10111522 |
_version_ | 1784604999362281472 |
---|---|
author | Moradi, Ghobad Alavian, Seyed Moayed Gholami, Fatemeh Ramezani, Rashid Ahangarzadeh, Leila Moradi, Yousef Sharafi, Heidar |
author_facet | Moradi, Ghobad Alavian, Seyed Moayed Gholami, Fatemeh Ramezani, Rashid Ahangarzadeh, Leila Moradi, Yousef Sharafi, Heidar |
author_sort | Moradi, Ghobad |
collection | PubMed |
description | Introduction: To realize the global goals of eliminating hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030, it is necessary to monitor the status of disease among target populations and undertake the required interventions. This study is the third round of surveys to determine the prevalence of hepatitis B and C infections among incarcerated individuals in different provinces of Iran. Methods: This study was conducted in five provinces of Iran (including Kurdistan, Ardabil, West Azerbaijan, Markazi, and Semnan) in 2019. The subjects of the study were selected from incarcerated people in prisons of all provinces that had not been studied in the previous two rounds of the surveys (in 2015 and 2016) in Iran. In this study, 15 prisons were selected and 2475 incarcerated individuals were enrolled into the study based on the multistage sampling method; the selected subjects were surveyed and their dried blood spot (DBS) samples were collected to test HBsAg and HCV-Ab. In cases with a reactive result for HCV-Ab, an HCV-RNA test was also performed on their serum samples. The relationships between independent variables and outcomes were evaluated via logistic regression. Results: Of all participants (2475 subjects) enrolled in the study, 54.18% were selected from northern provinces and 45.82% from the central provinces. The prevalence of HCV-Ab and HBsAg among incarcerated individuals was 5.66% (95% CI: 4.81% to 6.64%) and 2.42% (95% CI: 1.89% to 3.11%), respectively. Among HCV-seropositive individuals, 73.68% (95% CI: 64.70% to 81.01%) had current HCV infection (detectable HCV-RNA). The results showed that histories of imprisonment, drug use, unprotected sexual contact, drug injection, tattooing, and younger age in the first-time drug use in incarcerated individuals significantly increased the risk of HCV transmission. Among these behaviors, drug injection was more likely than other behaviors to result in contracting HCV in incarcerated individuals (OR: 22.91; 95% CI: 14.92–35.18; p < 0.001). Conclusion: To achieve international and national strategies targeted to eliminate HCV and HBV by 2030, it is necessary to pay special attention to prisons in Iran. It is recommended to continue HBV vaccination of eligible people in prisons. Developing screening and treatment protocols for individuals with HCV infection in prisons can help the country to achieve HCV elimination goals. |
format | Online Article Text |
id | pubmed-8619467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86194672021-11-27 Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019 Moradi, Ghobad Alavian, Seyed Moayed Gholami, Fatemeh Ramezani, Rashid Ahangarzadeh, Leila Moradi, Yousef Sharafi, Heidar Pathogens Article Introduction: To realize the global goals of eliminating hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030, it is necessary to monitor the status of disease among target populations and undertake the required interventions. This study is the third round of surveys to determine the prevalence of hepatitis B and C infections among incarcerated individuals in different provinces of Iran. Methods: This study was conducted in five provinces of Iran (including Kurdistan, Ardabil, West Azerbaijan, Markazi, and Semnan) in 2019. The subjects of the study were selected from incarcerated people in prisons of all provinces that had not been studied in the previous two rounds of the surveys (in 2015 and 2016) in Iran. In this study, 15 prisons were selected and 2475 incarcerated individuals were enrolled into the study based on the multistage sampling method; the selected subjects were surveyed and their dried blood spot (DBS) samples were collected to test HBsAg and HCV-Ab. In cases with a reactive result for HCV-Ab, an HCV-RNA test was also performed on their serum samples. The relationships between independent variables and outcomes were evaluated via logistic regression. Results: Of all participants (2475 subjects) enrolled in the study, 54.18% were selected from northern provinces and 45.82% from the central provinces. The prevalence of HCV-Ab and HBsAg among incarcerated individuals was 5.66% (95% CI: 4.81% to 6.64%) and 2.42% (95% CI: 1.89% to 3.11%), respectively. Among HCV-seropositive individuals, 73.68% (95% CI: 64.70% to 81.01%) had current HCV infection (detectable HCV-RNA). The results showed that histories of imprisonment, drug use, unprotected sexual contact, drug injection, tattooing, and younger age in the first-time drug use in incarcerated individuals significantly increased the risk of HCV transmission. Among these behaviors, drug injection was more likely than other behaviors to result in contracting HCV in incarcerated individuals (OR: 22.91; 95% CI: 14.92–35.18; p < 0.001). Conclusion: To achieve international and national strategies targeted to eliminate HCV and HBV by 2030, it is necessary to pay special attention to prisons in Iran. It is recommended to continue HBV vaccination of eligible people in prisons. Developing screening and treatment protocols for individuals with HCV infection in prisons can help the country to achieve HCV elimination goals. MDPI 2021-11-21 /pmc/articles/PMC8619467/ /pubmed/34832678 http://dx.doi.org/10.3390/pathogens10111522 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Moradi, Ghobad Alavian, Seyed Moayed Gholami, Fatemeh Ramezani, Rashid Ahangarzadeh, Leila Moradi, Yousef Sharafi, Heidar Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019 |
title | Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019 |
title_full | Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019 |
title_fullStr | Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019 |
title_full_unstemmed | Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019 |
title_short | Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019 |
title_sort | prevalence of hepatitis b and hepatitis c infections among incarcerated individuals in iran: a cross-sectional national bio-behavioral study in 2019 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619467/ https://www.ncbi.nlm.nih.gov/pubmed/34832678 http://dx.doi.org/10.3390/pathogens10111522 |
work_keys_str_mv | AT moradighobad prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019 AT alavianseyedmoayed prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019 AT gholamifatemeh prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019 AT ramezanirashid prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019 AT ahangarzadehleila prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019 AT moradiyousef prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019 AT sharafiheidar prevalenceofhepatitisbandhepatitiscinfectionsamongincarceratedindividualsiniranacrosssectionalnationalbiobehavioralstudyin2019 |